Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Neflamapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CervoMed Reveals Neflamapimod Boosts Brain Volume In Lewy Body
    CervoMed Reveals Neflamapimod Boosts Brain Volume In Lewy Body

    22 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/22/3278843/0/en/cervomed-announces-new-data-at-the-2026-aan-annual-meeting-that-demonstrated-neflamapimod-increased-basal-forebrain-volume-and-functional-connectivity-in-dementia-with-lewy-bodies.html

    GLOBENEWSWIRE
    22 Apr 2026
    Share Share
    Cervomed Updates Neflamapimod, Joins Biomarkers Panel
    Cervomed Updates Neflamapimod, Joins Biomarkers Panel

    07 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/07/3269002/0/en/CervoMed-to-Provide-Neflamapimod-Clinical-Program-Update-and-Participate-in-a-Panel-on-Biomarkers-at-2026-Lewy-Body-Dementia-Association-Annual-Meeting.html

    GLOBENEWSWIRE
    07 Apr 2026
    Share Share
    CervoMed Presents Neflamapimod Data At AD/PD 2026 Conference
    CervoMed Presents Neflamapimod Data At AD/PD 2026 Conference

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3258892/0/en/CervoMed-Announces-New-Data-at-the-AD-PD-2026-Scientific-Conference-that-Reinforce-Neflamapimod-s-Positive-Effects-in-Dementia-with-Lewy-Bodies-DLB-in-Patients-without-Alzheimer-s-.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    CervoMed To Present At AD/PD 2026 Conference
    CervoMed To Present At AD/PD 2026 Conference

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254471/0/en/CervoMed-Announces-Presentations-at-Upcoming-AD-PD-2026-Scientific-Conference.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    CervoMed Selects Formulation, Dosing for Phase 3 DLB Trial
    CervoMed Selects Formulation, Dosing for Phase 3 DLB Trial

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249254/0/en/CervoMed-Announces-Selection-of-Formulation-and-Dosing-Regimen-for-Planned-Phase-3-Trial-in-Patients-with-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share
    Cervomed Reveals Neflamapimod Slows Dementia Progression At CTAD
    Cervomed Reveals Neflamapimod Slows Dementia Progression At CTAD

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3200383/0/en/CervoMed-Announces-Late-Breaking-Data-at-the-18th-CTAD-Conference-Demonstrating-Neflamapimod-Significantly-Slows-Clinical-Progression-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.